Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter.
Eli Lilly is preparing for its third-quarter earnings report, with investor focus shifting from current blockbuster drugs to the potential of its experimental obesity treatment, retatrutide. While clinical trial results for the drug have shown significant weight loss, the company still needs to prove its efficacy in reducing cardiovascular risks.
Why it matters
As the obesity drug market expands, the long-term growth of pharmaceutical giants like Eli Lilly depends on the success of next-generation treatments beyond current market leaders.
Eli Lilly ( LLY -1.36% ) will report third-quarter earnings on Oct. 29, with the market paying particularly close attention to sales of its blockbuster diabetes and obesity drugs Mounjaro and Zepbound. But the company's experimental obesity treatment , retatrutide, could have a much greater influence on its long-term growth.
If you're unfamiliar, retatrutide is a once-weekly injection that targets three hormone receptors involved in regulating appetite, blood sugar, and metabolism. By comparison, Zepbound targets two. And thus far, clinical results have been impressive.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in